Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The newly developed Z583 is a potent and highly specific inhibitor of JAK3, with a favourable in vitro and in vivo safety profile and effectiveness in treatment of collagen-induced arthritis in mice.
A short questionnaire designed for use by dermatologists to screen patients with psoriasis can be used for the selection of individuals for MRI assessment of axial psoriatic arthritis.
New findings support the existence of an antigen presentation-independent mechanism known as the ‘cusp theory’ and the involvement of a newly discovered ‘lupus epitope’ in systemic lupus erythematosus susceptibility.
New research sheds light on how disruption of peripheral circadian rhythms mediates inflammation-induced intervertebral disc degeneration and suggests a therapeutic approach to target these mechanisms.
A new study reveals a non-canonical function for the histone demethylase JMJD1C that restrains plasma cell differentiation and protects mice from experimental arthritis.
Multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease are both hyperinflammatory disorders associated with infectious diseases, but are they distinct syndromes or do they exist along a continuum? A comparison of the host immune response in these illnesses provides surprising new insights.
Lack of understanding of the immunology of sarcoidosis has limited therapeutic progress. However, evidence from a small open-label trial suggests that treatment with the Janus kinase inhibitor tofacitinib can improve sarcoidosis symptoms, predominantly by inhibiting type 1 immunity.
In this Review, the authors summarize the genetic factors associated with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). They describe the findings from genetic association studies, their pathogenic significance and their implications for the classification, management and prognosis of AAV.
In this Review, Psarras, Wittmann and Vital discuss evidence of the production of type I interferons by cells and tissues other than haematopoietic cells. These interferons can have local effects, and their roles in the pathogenesis of systemic lupus erythematosus suggest the value of interferon-blocking therapies for treatment of this condition.
In this Review, the authors summarize and discuss regional differences in the prevalence and incidence of rheumatoid arthritis (RA), and describe temporal trends associated with the disease as well as evidence related to risk factors.
Gout can be effectively treated with long-term urate-lowering therapy. Current guidelines advocate the use of a treat-to-target serum urate strategy, with a target serum urate concentration of <5 mg/dl (<0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l), but specific targets are under debate. In this Review, the authors consider the rationale and evidence for the recommendations.
